Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry’s growing pipeline of programs that are differentiated by the frequency of ...

American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in its use ...

A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...